Changes in Beneficial Ownership · 4
Fulgent Genetics, Inc.
FLGTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-26
- Issuer
- Fulgent Genetics, Inc.
- Issuer CIK
- 0001674930
- Trading symbol
- FLGT
Reporting owner 1
- Name
- Kim Paul
- Reporting owner CIK
- 0001253820
- Relationship
- Officer
- Officer title
- CFO and Treasurer
- Address
- C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVENUE, EL MONTE, CA, 91731
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-26 | F · Form 4 | 2,748[F1] | D | 20.22 | 353,795 | D |
Table key
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.↩ 1
Signature 1
- Signed
- /s/ Paul Kim
- Date
- 2026-10-28
Company context
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.